ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SLDB Solid Biosciences Inc

14.25
0.00 (0.00%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 13.40
Ask Price 15.00
News -
Day High

Low
1.81

52 Week Range

High
14.99

Day Low
Company Name Stock Ticker Symbol Market Type
Solid Biosciences Inc SLDB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 14.25 04:00:00
Open Price Low Price High Price Close Price Prev Close
14.25
Trades Volume Avg Volume 52 Week Range
0 0 - 1.81 - 14.99
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 14.25 USD

Solid Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
538.04M 37.76M - 8.09M -85.98M -2.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Solid Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SLDB Message Board. Create One! See More Posts on SLDB Message Board See More Message Board Posts

Historical SLDB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.3814.9911.651113.51314,1240.876.50%
1 Month9.6814.998.6012.55334,9764.5747.21%
3 Months5.2914.995.209.03369,0488.96169.38%
6 Months2.5114.991.816.05430,27711.74467.73%
1 Year3.9214.991.816.00224,27610.33263.52%
3 Years87.7588.051.8127.82566,488-73.50-83.76%
5 Years143.25203.701.8155.88848,562-129.00-90.05%

Solid Biosciences Description

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Your Recent History

Delayed Upgrade Clock